SCHEMBL6809314

SCHEMBL6809314

CCCCCC(C)C12OCC(C)(CO1)CO2

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.35
SPHK1 Q9NYA1 1/20 0.31
CA1 P00915 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6809307 0.94 CHRM2 (0.31) OPRM1
SCHEMBL11287401 0.71 DNM1 (0.32) OPRM1CA1
SCHEMBL6809310 0.69
SCHEMBL8517438 0.69 OPRM1 (0.42) OPRM1SPHK1CA1
SCHEMBL6753724 0.67
SCHEMBL1668247 0.67 OPRM1 (0.33) OPRM1SPHK1
SCHEMBL19171390 0.67
SCHEMBL8185810 0.66 MAPT (0.46) CA1
SCHEMBL6813934 0.65
SCHEMBL18746534 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8784791-B2 Method for preparing water-soluble polymer derivatives bearing an N-succinimidyl ester NEKTAR THERAPEUTICS (US) 2014-07-22 US disclosed
US-20130231490-A1 METHOD FOR PREPARING WATER-SOLUBLE POLYMER DERIVATIVES BEARING AN N-SUCCINIMIDYL ESTER NEKTAR THERAPEUTICS (US) 2013-09-05 US disclosed
US-20120209027-A1 Method for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid NEKTAR THERAPEUTICS (US) 2012-08-16 US disclosed
US-8182801-B2 Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid NEKTAR THERAPEUTICS (US) 2012-05-22 US disclosed
US-20090264600-A1 Method for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120209027-A1 Method for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid SI, APEH, PGA5 OPRM1 1595/4885SPHK1 3372/4885CA1 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.